BioMarin starts Phase 1 BMN 673 trial
The open-label, two-arm dose escalation trial intends to establish the maximum tolerated dose of BMN 673. The trial will also evaluate the pharmacodynamics, pharmacokinetics, safety and preliminary efficacy
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.